Skip to main content

Small Molecule Deal Benchmarks in Neurology

Median Upfront
$343M
Range: $171M - $519M
Total Deal Value
$3.0B
Range: $1.8B - $4.3B
Royalty Rate
12.4% - 19.8%
Tiered up to 23.8%
Dev Milestones
$890M
Range: $545M - $1.2B
Model Your Deal

Market Analysis

Small Molecule therapies in neurology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 small molecule asset in neurology is $343M, with total deal values reaching $3.0B. Development milestones average $890M, while regulatory milestones contribute $971M.

The neurology small molecule landscape is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for small molecule neurology deals range from 12.4% to 19.8% at the base tier, with tiered escalation reaching 16.4%-23.8% on blockbuster sales. Commercial milestones averaging $836M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a small molecule neurology licensing deal?
Based on our analysis, Phase 2 small molecule licensing deals in neurology average $343M in upfront payments, with a range of $171M to $519M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for small molecule neurology transactions?
The median total deal value for Phase 2 small molecule assets in neurology is $3.0B, ranging from $1.8B to $4.3B. This includes development milestones ($890M), regulatory milestones ($971M), and commercial milestones ($836M).
What royalty rates are standard for small molecule deals in neurology?
Base royalty rates for small molecule neurology transactions range from 12.4% to 19.8%, with tiered escalations reaching 16.4%-23.8% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in small molecule neurology deals?
Small Molecule neurology deals allocate approximately 89% of total deal value to milestones. Development milestones ($890M) make up the largest share, followed by commercial milestones ($836M) and regulatory milestones ($971M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Monoclonal Antibody in Neurology

View

Bispecific Antibody in Neurology

View

Small Molecule in Oncology

View

Small Molecule in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included